Vistagen股价暴跌,因治疗社交焦虑症的药物在后期临床试验中未达到主要目标

路透中文
Jun 30
BUZZ-Vistagen股价暴跌,因治疗社交焦虑症的药物在后期临床试验中未达到主要目标

6月30日 - ** Vistagen(VTGN.O)股价在盘前交易中暴跌67%,至0.25美元

** 这家生物技术公司表示,其用于治疗社交焦虑障碍(一种以对社交场合产生强烈恐惧为特征的疾病)的实验性鼻喷雾剂,在后期临床试验中未能优于安慰剂

** 该公司称,在模拟公开演讲测试中,接受法塞迪诺尔治疗的患者其焦虑程度降低幅度与接受安慰剂的患者相当

** 另一项分析发现,与安慰剂相比,社交焦虑最严重的患者从该药物中获益更多

** VTGN表示,法塞迪诺尔耐受性良好,其安全性特征与前期研究一致

** 计划就一项新研究与美国食品药品监督管理局(FDA)进行磋商,该研究侧重于社交焦虑障碍的整体治疗,而非短期症状

** 预计其现金储备足以支撑运营至2027年

** 截至上一交易日收盘,该股年内累计涨幅约为15%

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10